We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Edwards Lifesciences (EW) Gains But Lags Market: What You Should Know
Read MoreHide Full Article
Edwards Lifesciences (EW - Free Report) closed at $121.91 in the latest trading session, marking a +0.89% move from the prior day. This change lagged the S&P 500's 1.12% gain on the day. Elsewhere, the Dow gained 1.01%, while the tech-heavy Nasdaq lost 0.08%.
Heading into today, shares of the medical device maker had gained 13.84% over the past month, outpacing the Medical sector's gain of 7.36% and the S&P 500's gain of 4.63% in that time.
Edwards Lifesciences will be looking to display strength as it nears its next earnings release, which is expected to be April 26, 2022. On that day, Edwards Lifesciences is projected to report earnings of $0.58 per share, which would represent year-over-year growth of 7.41%. Our most recent consensus estimate is calling for quarterly revenue of $1.31 billion, up 7.57% from the year-ago period.
For the full year, our Zacks Consensus Estimates are projecting earnings of $2.56 per share and revenue of $5.72 billion, which would represent changes of +15.32% and +9.41%, respectively, from the prior year.
Any recent changes to analyst estimates for Edwards Lifesciences should also be noted by investors. Recent revisions tend to reflect the latest near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. Edwards Lifesciences is currently sporting a Zacks Rank of #3 (Hold).
Digging into valuation, Edwards Lifesciences currently has a Forward P/E ratio of 47.12. Its industry sports an average Forward P/E of 32.4, so we one might conclude that Edwards Lifesciences is trading at a premium comparatively.
It is also worth noting that EW currently has a PEG ratio of 3.39. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The Medical - Instruments industry currently had an average PEG ratio of 2.14 as of yesterday's close.
The Medical - Instruments industry is part of the Medical sector. This group has a Zacks Industry Rank of 156, putting it in the bottom 39% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow EW in the coming trading sessions, be sure to utilize Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Edwards Lifesciences (EW) Gains But Lags Market: What You Should Know
Edwards Lifesciences (EW - Free Report) closed at $121.91 in the latest trading session, marking a +0.89% move from the prior day. This change lagged the S&P 500's 1.12% gain on the day. Elsewhere, the Dow gained 1.01%, while the tech-heavy Nasdaq lost 0.08%.
Heading into today, shares of the medical device maker had gained 13.84% over the past month, outpacing the Medical sector's gain of 7.36% and the S&P 500's gain of 4.63% in that time.
Edwards Lifesciences will be looking to display strength as it nears its next earnings release, which is expected to be April 26, 2022. On that day, Edwards Lifesciences is projected to report earnings of $0.58 per share, which would represent year-over-year growth of 7.41%. Our most recent consensus estimate is calling for quarterly revenue of $1.31 billion, up 7.57% from the year-ago period.
For the full year, our Zacks Consensus Estimates are projecting earnings of $2.56 per share and revenue of $5.72 billion, which would represent changes of +15.32% and +9.41%, respectively, from the prior year.
Any recent changes to analyst estimates for Edwards Lifesciences should also be noted by investors. Recent revisions tend to reflect the latest near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. Edwards Lifesciences is currently sporting a Zacks Rank of #3 (Hold).
Digging into valuation, Edwards Lifesciences currently has a Forward P/E ratio of 47.12. Its industry sports an average Forward P/E of 32.4, so we one might conclude that Edwards Lifesciences is trading at a premium comparatively.
It is also worth noting that EW currently has a PEG ratio of 3.39. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The Medical - Instruments industry currently had an average PEG ratio of 2.14 as of yesterday's close.
The Medical - Instruments industry is part of the Medical sector. This group has a Zacks Industry Rank of 156, putting it in the bottom 39% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow EW in the coming trading sessions, be sure to utilize Zacks.com.